Ones To Watch News
Refine Search
Biotechnology
LenioBio, a German biotech company focused on cell-free protein production, and UK-based enzymatic DNA production Touchlight have announced a supply agreement. 3 July 2024
Biotechnology
Beacon Therapeutic, Series B, financing 3 July 2024
Biotechnology
Cartesian Therapeutics, a biotech seeking to develop mRNA cell therapies for autoimmune diseases, was trading nearly 20% lower early in Tuesday’s trading. 3 July 2024
Pharmaceutical
Oxford, UK-based ThirtyFiveBio, a company specializing in GPR35 inhibitors for gastrointestinal diseases, has announced receipt of a grant from Innovate UK. 2 July 2024
Pharmaceutical
Cambridge, UK-based Mission Therapeutics, a clinical-stage biotech, has received $5.2 million in funding from The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK. 2 July 2024
Pharmaceutical
US pharma major Eli Lilly has followed up last year’s $1.4 billion acquisition of radiopharmaceuticals firm POINT Biopharma Global with another deal in the field. 2 July 2024
Biotechnology
Shares in TRACON Pharmaceuticals have fallen by a third, after the San Diego-based firm announced the termination of work on its candidate envafolimab. 2 July 2024
Biotechnology
Dutch life sciences venture capital firm Forbion has announced the hiring of Josh Brumm, former president and chief executive of Dyne Therapeutics, as a general partner. 1 July 2024
Biotechnology
TwoStep Therapeutics, a biotech start-up developing targeted therapies for solid tumors, has officially launched after securing $6.5 million in seed funding. 27 June 2024
Biotechnology
AI-focused start-up Formation Bio has raised $372 million in a series D financing. 27 June 2024
Biotechnology
US RNA specialist Wave Life Sciences has presented positive results from its Phase Ib/IIa SELECT-HD trial of WVE-003, which is being developed as a potential disease modifying therapeutic for Huntington’s disease (HD). 26 June 2024
Pharmaceutical
NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotechnology company focused on cardiometabolic diseases, has raised around $70 million through a private share placement. 26 June 2024
Pharmaceutical
In a filing with the US Securities and Exchange Commission (SEC), Californian biotech Alumis has revealed it aims to raise around $300 million in its upcoming initial public offering (IPO). 25 June 2024
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze